Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
The PROCURE study utilized Delphi methodology to generate consensus regarding the clinical utility of GEP tests, including Veracyte’s Prosigna Breast Cancer Assay, in breast cancer treatment. A scientific committee of eight breast cancer experts developed a questionnaire, which was used to survey 133 specialists from 11 European countries. Consensus was achieved when at least 70 percent of respondents agreed on a topic. Among the findings:
- 88 percent of participants give importance to GEP prognostic results when deciding on chemotherapy usage in the adjuvant setting for early-stage breast cancer patients whose disease has not spread to the lymph nodes;
- 75 percent also consider it important when deciding on chemotherapy in the adjuvant setting in early-stage patients with 1 to 3 positive lymph nodes;
- 76 percent of participants agreed on the clinical utility of molecular subtype information from GEP testing to assess likelihood of disease recurrence among early-stage breast cancer patients who are hormone-receptor positive; and
- 75 percent think the use of molecular subtype information is useful to identify such patients who may safely avoid chemotherapy.
“Our findings show that use of gene expression profile tests has become standard of care among physicians in
Also among the findings, 67 percent of respondents believe that GEP tests can help physicians determine the most appropriate type of chemotherapy treatment.
“While a large-scale, prospective trial to determine such predictive information from GEP testing would be valuable, our findings suggest more education is needed among breast cancer specialists regarding the role that GEP tests play today,” said
“We believe the PROCURE study will provide much-needed clarity to breast cancer clinicians and their patients about the clinical utility of GEP testing,”
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, our statements associated with study data related to our Prosigna Breast Cancer Assay. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to our ability to launch, commercialize and receive reimbursement for our products and our ability to successfully integrate our business deals and execute on our business plans. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005302/en/
Director, Investor Relations
Vice President of